INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease... Show more
INmune Bio is a late-stage biotechnology company focused on inflammation and immunology, and its quarterly earnings serve as a window into both its cash position and its regulatory progress. With no commercial products yet on the market, the third quarter was less about revenue and more about execution on Ebstrocel, its lead cellular medicine for recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe genetic skin disorder. Investors are watching closely because the company is approaching a pivotal transition from clinical development toward potential approval. The timeline for regulatory filings, the pace of cash burn, and financing decisions all carry outsized weight for a pre-revenue biotech with a narrow runway.
For the third quarter ended September 30, 2026, INmune Bio reported a net loss attributable to common stockholders of approximately $4.7 million, compared with roughly $6.5 million in the year-ago quarter. The company recorded no product revenue during the period. Research and development expenses totaled approximately $3.2 million, down from about $4.9 million a year earlier, while general and administrative expenses were approximately $1.8 million, down from $2.5 million.
The narrowing loss partly reflects lower spending following the wind-down of its earlier Alzheimer's disease trial work. On a per-share basis, the quarterly loss narrowed to roughly $0.17 from $0.24 a year ago. As of September 30, 2026, cash and cash equivalents were approximately $16.3 million. In October, the company raised about $4.5 million in gross proceeds from the sale of common stock and warrants, and management stated that its cash resources are sufficient to fund operations through the third quarter of 2027. Approximately 31 million shares were outstanding as of November 5, 2026.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like INmune Bio, it offers a streamlined way to surface relevant opportunities across the broader market.
Shares of INmune Bio traded lower following the third-quarter report, as investors weighed the combination of a narrowed loss against another regulatory timeline adjustment and fresh dilution. The company's announcement that its UK Marketing Authorization Application (MAA) for Ebstrocel is now targeted for early February 2027 — rather than the late-2026 window previously discussed — drew particular scrutiny. The October registered direct offering also increased the share count, adding to dilution concerns. At the same time, management framed the revised filing strategy as an upgrade, arguing that a complete application could ultimately support a faster approval decision.
The most important near-term catalyst remains the submission of a complete Ebstrocel MAA to the UK's Medicines and Healthcare products Regulatory Agency (MHRA), now targeted for early February 2027. Management anticipates an MHRA review and response within roughly three to six months of filing, supporting a potential UK approval in mid-2027.
In the United States, the company plans an FDA Type B meeting to clarify the regulatory pathway, followed by a targeted Biologics License Application (BLA) submission in mid-2027. Investors should monitor whether these timelines hold, since the company has adjusted its filing dates on multiple occasions. The status of the European Medicines Agency (EMA) filing, which has been deprioritized, is another factor to watch.
On the commercial front, the partnership with Uniphar to establish named-patient access in selected European, Middle Eastern, and North African markets could provide an early source of revenue before full approvals are secured, though management has not provided a forecast or first-sale date. For XPro, the company intends to defer significant company-funded investment until Ebstrocel is approved, while continuing indication-selection work with Quantum Computing Inc. Cash burn, financing needs, and the progress of a planned confirmatory trial expected to open in early 2027 will also shape the story in the quarters ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of therapies that harness the patient's immune system to treat cancer
Industry Biotechnology